Lecanemab for Alzheimer's disease: tempering hype and hope
Lecanemab for Alzheimer's disease: tempering hype and hope
About this item
Full title
Author / Creator
Publisher
London: Elsevier Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: Elsevier Ltd
Subjects
More information
Scope and Contents
Contents
After 18 months of treatment, lecanemab reduced cognitive decline, as measured by the Clinical Dementia Rating-Sum of Boxes (CDR-SB), which quantifies symptom severity across a range of cognitive and functional domains, by 27% compared with placebo—an absolute difference of 0·45 points (change from baseline 1·21 for lecanemab vs 1·66 with placebo,...
Alternative Titles
Full title
Lecanemab for Alzheimer's disease: tempering hype and hope
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2747007348
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2747007348
Other Identifiers
ISSN
0140-6736
E-ISSN
1474-547X
DOI
10.1016/S0140-6736(22)02480-1
